Efforts to prevent and halt autoimmune beta cell destruction

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 3, 2010, Pages 527-539

  Haller, Michael J ^a   Atkinson, Mark A ^b   Schatz, Desmond A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Combination therapy; Intervention; Prevention; Type 1 diabetes

Indexed keywords

ABATACEPT; ALPHA 1 ANTITRYPSIN; AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; BASILIXIMAB; BCG VACCINE; COLECALCIFEROL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DIAMYD; DOCOSAHEXAENOIC ACID; GLUTAMATE DECARBOXYLASE 65; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INSULIN; KETOTIFEN; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OTELIXIZUMAB; PLACEBO; PREDNISONE; PROTEIN C; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TEPLIZUMAB; THYMOCYTE ANTIBODY; THYMOGLUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALLOTRANSPLANTATION; ALOPECIA; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; APLASTIC ANEMIA; AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOTRANSPLANTATION; CELL THERAPY; CLINICAL TRIAL; CYTOKINE RELEASE SYNDROME; DENDRITIC CELL; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EARLY INTERVENTION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; IMPAIRED GLUCOSE TOLERANCE; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; LUPUS VULGARIS; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SECONDARY PREVENTION; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; TESTIS DISEASE; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION; WEGENER GRANULOMATOSIS;

EID: 77955738129     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.05.006     Document Type: Review

References (58)

1. Staeva-Vieira T., Peakman M., von Herrath M. Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007, 148(1):17-31.
2. Haller M.J., Atkinson M.A., Schatz D. Type 1 diabetes mellitus: etiology, presentation, and management. Pediatr Clin North Am 2005, 52(6):1553-1578.
3. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358(9277):221-229.
4. Atkinson M.A., Maclaren N.K., Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990, 39(8):933-937.
5. Kupila A., Sipila J., Keskinen P., et al. Intranasally administered insulin intended for prevention of type 1 diabetes-a safety study in healthy adults. Diabetes Metab Res Rev 2003, 19(5):415-420.
6. Harrison L.C., Honeyman M.C., Steele C.E., et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004, 27(10):2348-2355.
7. Harrison L. INIT II study web site 2010. Available at:, Accessed January 20, 2010. http://www.diabetestrials.org/initii.html.
8. Bonifacio E. JDRF funded research: pre-point 2010. Available at:, Accessed January 20, 2009. http://onlineapps.jdfcure.org/AbstractReport.cfm%3Fgrant_id%3D26014%26abs_type%3DLAY.
9. Orban T., Farkas K., Jalahej H., et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010, 34(4):408-415.
10. Tisch R., Yang X.D., Liblau R.S., et al. Administering glutamic acid decarboxylase to NOD mice prevents diabetes. J Autoimmun 1994, 7(6):845-850.
11. Ludvigsson J., Faresjo M., Hjorth M., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359(18):1909-1920.
12. Silverstein J., Maclaren N., Riley W., et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988, 319(10):599-604.
13. Bougneres P.F., Carel J.C., Castano L., et al. Journ Annu Diabetol Hotel Dieu 1987, 181-186. [in French].
14. Carel J.C., Boitard C., Eisenbarth G., et al. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. J Autoimmun 1996, 9(6):739-745.
15. Eisenbarth G.S., Srikanta S., Jackson R., et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985, 2(6):271-276.
16. Gale E.A.M. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363(9413):925-931.
17. Bohmer K.P., Kolb H., Kuglin B., et al. Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen. Diabetes Care 1994, 17(2):138-141.
18. Huppmann M., Baumgarten A., Ziegler A.G., et al. Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes Care 2005, 28(5):1204-1206.
19. Zhang B., Lu Y., Campbell-Thompson M., et al. Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes 2007, 56(5):1316-1323.
20. Haller M.J., Wasserfall C.H., McGrail K.M., et al. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care 2009, 32(11):2041-2046.
21. Huurman V.A., van der Meide P.E., Duinkerken G., et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 2008, 152(3):488-497.
22. TRIGR Study Group Study design of the trial to reduce IDDM in the genetically at risk (TRIGR). Pediatr Diabetes 2007, 8(3):117-137.
23. Herold K.C., Bluestone J.A., Montag A.G., et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992, 41(3):385-391.
24. Sherry N.A., Chen W., Kushner J.A., et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007, 148(11):5136-5144.
25. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352(25):2598-2608.
26. Haller M.J., Schatz D.A. CD3-antibody therapy in new-onset type 1 diabetes mellitus. N Engl J Med 2005, 353(19):2086-2087. [author reply: 2086-7].
27. Xiu Y., Wong C.P., Bouaziz J.D., et al. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol 2008, 180(5):2863-2875.
28. Fiorina P., Vergani A., Dada S., et al. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes 2008, 57(11):3013-3024.
29. Ugrasbul F., Moore W.V., Tong P.Y., et al. Prevention of diabetes: effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB rat. Pediatr Diabetes 2008, 9(6):596-601.
30. Gottlieb P.A., Quinlan S., Krause-Steinrauf H., et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new onset type 1 diabetes. Diabetes Care 2010, 33(4):826-832.
31. Rudd C.E., Taylor A., Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009, 229(1):12-26.
32. Korolija M., Renar I.P., Hadzija M., et al. Association of PTPN22 C1858T and CTLA-4 A49G polymorphisms with type 1 diabetes in Croatians. Diabetes Res Clin Pract 2009, 86(3):e54-e57.
33. Feng X., Kajigaya S., Solomou E.E., et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 2008, 111(7):3675-3683.
34. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21(7):1387-1394.
35. Saccardi R., Kozak T., Bocelli-Tyndall C., et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006, 12(6):814-823.
36. Fassas A., Anagnostopoulos A., Kazis A., et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997, 20(8):631-638.
37. Frickhofen N., Heimpel H., Kaltwasser J.P., et al. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003, 101(4):1236-1242.
38. Kool J., de Keizer R.J., Siegert C.E. Antithymocyte globulin treatment of orbital Wegener granulomatosis: a follow-up study. Am J Ophthalmol 1999, 127(6):738-739.
39. McSweeney P.A., Nash R.A., Sullivan K.M., et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002, 100(5):1602-1610.
40. Molldrem J.J., Leifer E., Bahceci E., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002, 137(3):156-163.
41. Musso M., Porretto F., Crescimanno A., et al. Intense immunosuppressive therapy followed by autologous peripheral blood selected progenitor cell reinfusion for severe autoimmune disease. Am J Hematol 2001, 66(2):75-79.
42. Rosenfeld S., Follmann D., Nunez O., et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003, 289(9):1130-1135.
43. Stratton R.J., Wilson H., Black C.M. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001, 40(1):84-88.
44. Schatz D.A., Riley W.J., Silverstein J.H., et al. Long-term immunoregulatory effects of therapy with corticosteroids and anti-thymocyte globulin. Immunopharmacol Immunotoxicol 1989, 11(2-3):269-287.
45. Saudek F., Havrdova T., Boucek P., et al. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 2004, 1(2):80-88.
46. Couri C.E., Oliveira M.C., Stracieri A.B., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009, 301(15):1573-1579.
47. Parker M.J., Xue S., Alexander J.J., et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 2009, 58(10):2277-2284.
48. Voltarelli J.C., Couri C.E., Stracieri A.B., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007, 297(14):1568-1576.
49. Gitelman S.E., Haller M.J., Schatz D. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009, 302(6):624. [author reply: 624-5].
50. Haller M.J., Viener H.L., Wasserfall C., et al. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol 2008, 36(6):710-715.
51. Lande R., Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 2010, 1183:89-103.
52. Ma L., Qian S., Liang X., et al. Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-kappaB activity. Diabetes 2003, 52(8):1976-1985.
53. Phillips B.E., Giannoukakis N., Trucco M. Dendritic cell mediated therapy for immunoregulation of type 1 diabetes mellitus. Pediatr Endocrinol Rev 2008, 5(4):873-879.
54. Tyndall A., Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplant 2009, 43(11):821-828.
55. Fiorina P., Jurewicz M., Augello A., et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009, 183(2):993-1004.
56. Madec A.M., Mallone R., Afonso G., et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009, 52(7):1391-1399.
57. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9(3):239-244.
58. Atkinson M.A. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease?. Diabetes 2005, 54(5):1253-1263.